ISSUE 1306
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
An old conjugated estrogens vaginal cream (Premarin Vaginal Cream – Wyeth) has been newly approved by the FDA specifically for treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause. Synthetic conjugated estrogens A vaginal cream (Barr) has also been approved for this indication, but has not yet been marketed.
Vulvovaginal Atrophy – Other vaginal estrogens are approved for treatment of vulvovaginal atrophy, but not specifically for dyspareunia. Vulvovaginal atrophy is common among postmenopausal women and causes itching, dryness and pain with intercourse. Systemic estrogen (tablets, patches, etc.) effectively treats the symptoms of vaginal atrophy, but the risks of such treatment include breast cancer, venous thromboembolism and stroke.1
PHARMACOLOGY — Each gram of the cream contains 0.625 mg of conjugated
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1306b
Electronic, downloadable article - $45